Sign the pledge! If elimination by 2030 is to be achieved, the global community needs to act immediately. More

São Paulo, Brazil – November 2nd 2017.
At the occasion of the World Hepatitis Summit, a large coalition of patients, clinicians, social workers, representatives of the drug using community, researchers, and public health experts express their whole-hearted support to the commitment of the World (...) More

Petition to stop Gilead’s anti-diversion program that violates physician and patient rights to protect its profit. More

1-3 March 2019, Penang, Malaysia
Positive Malaysian Treatment Access and Advocacy Group (MTAAG+), with partners Treatment Action Group and the Foundation for Innovative New Diagnostics, convened the first advocacy workshop on hepatitis C virus (HCV) diagnostics. The workshop presented the (...) More

In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This Hepatitis C World Community Advisory Board meeting was an opportunity for activists to present demands (...) More

Georgia has a huge burden of hepatitis C, with a national prevalence rate of 7.1% for HCV antibodies. People who inject drugs (PWID) are particularly affected and hence form a vulnerable group. A study conducted by Médecins du Monde in 2012 found that 92% of the PWID in Tbilissi had HCV (...) More